论文部分内容阅读
目的探讨肿瘤标志物CA153、CEA、CA125在乳腺癌诊断中的应用和临床价值。方法对1270例患者行CA153、CEA、CA125检查,其中乳腺癌患者378例、乳腺良性病变患者492例、女性健康体检者400例。结果CA153、CEA、CA125的检测结果从正常对照者到乳腺癌患者之间呈逐渐增高的趋势,3组间差异有统计学意义(P<0.05)。乳腺癌患者三项指标联合检测阳性率显著高于单项检测阳性率,具有统计学差异(P<0.05)。结论CA153、CEA、CA125的联合检测对于乳腺癌的诊断和鉴别诊断具有一定的价值,但仍需寻找更有价值的乳腺肿瘤标志物。
Objective To investigate the application and clinical value of tumor markers CA153, CEA and CA125 in the diagnosis of breast cancer. Methods A total of 1270 patients underwent CA153, CEA and CA125 examinations, including 378 cases of breast cancer, 492 cases of benign breast disease and 400 cases of female health examination. Results The results of CA153, CEA and CA125 showed a trend of increasing from the normal controls to the patients with breast cancer. The differences among the three groups were statistically significant (P <0.05). The positive rate of combined detection of three indexes in patients with breast cancer was significantly higher than that of single detection (P <0.05). Conclusion The combined detection of CA153, CEA and CA125 is valuable for the diagnosis and differential diagnosis of breast cancer. However, it is still necessary to find more valuable breast tumor markers.